IASLC World Conference on Lung Cancer | Conference

Dr. Tolba on Targeting NRG1 Fusions in NSCLC

September 10th 2019

Khaled A. Tolba MD, MBBCh, assistant professor of medicine, School of Medicine, Oregon Health & Science University, provides data from a study on targeting NRG1 fusions in non-small cell lung cancer.

Larotrectinib Is Highly Active in Patients With NTRK Fusion+ NSCLC

September 10th 2019

Anna F. Farago, MD, PhD, assistant professor of medicine, Harvard Medical School, discusses the updated activity of larotrectinib in NTRK fusion–positive lung cancer.

Selpercatinib Achieves High Response Rate in RET+ NSCLC

September 10th 2019

Almost 70% of patients with previously treated RET-fusion–positive non–small cell lung cancer had objective responses to the RET inhibitor selpercatinib (LOXO-292), according to data from the phase I/II LIBRETTO-001 trial presented at the 2019 World Conference on Lung Cancer.

Durvalumab Combo Improves Survival in Frontline Small Cell Lung Cancer

September 9th 2019

Patients with untreated extensive-stage small cell lung cancer had statistically significant improvement in overall survival when the PD-L1 inhibitor durvalumab (Imfinzi) was added to chemotherapy.

Afatinib Continues to Showcase Activity in NRG1 Fusions in Lung Cancer

September 9th 2019

Findings from a small case series of patients with lung cancer added to evidence that afatinib is a potentially effective treatment in patients with lung adenocarcinoma who have NRG1 fusions.

Bemcentinib/Pembrolizumab Combo Active in Chemo-Refractory NSCLC

September 9th 2019

The first-in-class AXL inhibitor bemcentinib (BGB324) demonstrated activity in combination with the PD-1 inhibitor pembrolizumab in patients with advanced non–small cell lung cancer who had no prior exposure to immunotherapy.

Expert Discusses Novel Agents in Development Targeting EGFR, HER2+ NSCLC

September 9th 2019

Pasi A. Jänne, MD, PhD, discusses 3 studies of novel agents for targeting EGFR-mutant and HER2-positive lung cancers and the next steps in getting the research to cancer clinics.

AMG 510 Highly Active in KRAS+ NSCLC

September 8th 2019

The investigational KRAS inhibitor AMG 510 induced near-universal disease control in patients with advanced non–small cell lung cancer with KRAS mutations.

Dr. Garassino on Immunotherapy in EGFR-Mutated Lung Cancer

November 1st 2017

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses immunotherapy for patients with EGFR-mutated lung cancer.

Dr. Oxnard on the Role of Osimertinib in the TATTON Trial for Lung Cancer

November 1st 2017

Geoffrey R. Oxnard, MD, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the role of osimertinib (Tagrisso) in the TATTON trial for patients with lung cancer.

Dr. Camidge on the Unmet Needs for Lung Cancer

October 25th 2017

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses unmet needs for patients with lung cancer.

Dr. Drilon on MET-Amplified Lung Cancer

October 25th 2017

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of MET in patients with lung cancer.

Dr. Garassino Discusses Recent Pivotal Immunotherapy Findings in NSCLC

October 19th 2017

Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses some of the recent exciting results regarding immunotherapy in non-small cell lung cancer (NSCLC).

Frontline Pembrolizumab More Than Doubles OS in PD-L1+ NSCLC

October 19th 2017

Two-year results showed that frontline pembrolizumab (Keytruda) more than doubled median overall survival compared with standard chemotherapy in patients with high PD-L1 expressing non–small cell lung cancer

Ado-Trastuzumab Emtansine Shows Activity in HER2-Mutated, Amplified Lung Cancer

October 19th 2017

Ado-trastuzumab emtansine (Kadcyla) is active and well tolerated in patients with advanced HER2-mutant or amplified lung cancers as identified by next generation sequencing.

Dr. Doebele on Significant Findings of Entrectinib in Patients With ROS1+ NSCLC

October 19th 2017

Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses the significance of the results of a trial exploring entrectinib in patients with ROS1-positive non

Entrectinib Impresses for ROS1-Positive NSCLC

October 18th 2017

Treatment with entrectinib induced an objective response rate of 68.8% by blinded independent central review, which included 2 complete responses (6.3%), for patients with ROS1 fusion-positive advanced non–small cell lung cancer.

Ensartinib Effective, Well-Tolerated in Patients With ALK+, TKI-Naive NSCLC

October 18th 2017

The potent small molecule TKI ensartinib has shown promise and meaningful intercranial activity in ALK-positive, TKI-naïve patients with non–small cell lung cancer.

Frontline Lorlatinib Induces 90% Response in ALK+ NSCLC

October 18th 2017

Lorlatinib induced an objective response rate of 90% in treatment-naïve patients with ALK-positive non–small cell lung cancer.

Durvalumab Delivers on QoL Post Chemo RT in PACIFIC Trial

October 18th 2017

Patient reported outcomes from the PACIFIC trial of durvalumab versus placebo after chemoradiation in locally advanced unresectable NSCLC show that durvalumab had no serious impact on quality of life.